Take Solutions Limited (TAKE) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.122x

Based on the latest financial reports, Take Solutions Limited (TAKE) has a cash flow conversion efficiency ratio of -0.122x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-31.39 Million ≈ $-339.47K USD) by net assets (Rs256.29 Million ≈ $2.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Take Solutions Limited balance sheet quality to measure how much of total assets are equity-financed.

Take Solutions Limited - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Take Solutions Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TAKE operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Take Solutions Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Take Solutions Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Wing Yip Food (China) Holdings Group Limited
KQ:900340
-0.005x
Mural Oncology plc
NASDAQ:MURA
-0.335x
Ihlas Gayrimenkul Proje Gelistirme ve Ticaret AS
IS:IHLGM
0.012x
IFCA MSC Bhd
KLSE:0023
-0.058x
Metalstech Ltd
AU:MTC
-0.074x
OpenSys M Bhd
KLSE:0040
-0.145x
Loop Industries Inc
NASDAQ:LOOP
0.286x
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
0.712x

Annual Cash Flow Conversion Efficiency for Take Solutions Limited (2007–2025)

The table below shows the annual cash flow conversion efficiency of Take Solutions Limited from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Take Solutions Limited worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs205.27 Million
≈ $2.22 Million
Rs-163.66 Million
≈ $-1.77 Million
-0.797x +24.06%
2024-03-31 Rs-88.73 Million
≈ $-959.58K
Rs93.16 Million
≈ $1.01 Million
-1.050x -669.68%
2023-03-31 Rs1.09 Billion
≈ $11.74 Million
Rs200.16 Million
≈ $2.16 Million
0.184x +12.40%
2022-03-31 Rs1.81 Billion
≈ $19.53 Million
Rs296.17 Million
≈ $3.20 Million
0.164x +36.32%
2021-03-31 Rs11.24 Billion
≈ $121.59 Million
Rs1.35 Billion
≈ $14.63 Million
0.120x -9.68%
2020-03-31 Rs15.85 Billion
≈ $171.45 Million
Rs2.11 Billion
≈ $22.83 Million
0.133x +96.40%
2019-03-31 Rs15.27 Billion
≈ $165.18 Million
Rs1.04 Billion
≈ $11.20 Million
0.068x -25.00%
2018-03-31 Rs13.37 Billion
≈ $144.56 Million
Rs1.21 Billion
≈ $13.07 Million
0.090x +54.17%
2017-03-31 Rs9.53 Billion
≈ $103.08 Million
Rs558.98 Million
≈ $6.05 Million
0.059x -73.41%
2016-03-31 Rs6.72 Billion
≈ $72.62 Million
Rs1.48 Billion
≈ $16.02 Million
0.221x +72.74%
2015-03-31 Rs5.80 Billion
≈ $62.78 Million
Rs741.25 Million
≈ $8.02 Million
0.128x -33.69%
2014-03-31 Rs5.18 Billion
≈ $56.06 Million
Rs998.25 Million
≈ $10.80 Million
0.193x -23.03%
2013-03-31 Rs4.66 Billion
≈ $50.41 Million
Rs1.17 Billion
≈ $12.61 Million
0.250x -17.75%
2012-03-31 Rs3.80 Billion
≈ $41.05 Million
Rs1.15 Billion
≈ $12.49 Million
0.304x +45.36%
2011-03-31 Rs2.82 Billion
≈ $30.48 Million
Rs589.85 Million
≈ $6.38 Million
0.209x +341.83%
2010-03-31 Rs3.86 Billion
≈ $41.70 Million
Rs182.63 Million
≈ $1.98 Million
0.047x -72.58%
2009-03-31 Rs3.86 Billion
≈ $41.73 Million
Rs666.62 Million
≈ $7.21 Million
0.173x +1.88%
2008-03-31 Rs2.98 Billion
≈ $32.28 Million
Rs506.13 Million
≈ $5.47 Million
0.170x +25.11%
2007-03-31 Rs885.44 Million
≈ $9.58 Million
Rs120.02 Million
≈ $1.30 Million
0.136x --

About Take Solutions Limited

NSE:TAKE India Biotechnology
Market Cap
$35.36 Million
Rs3.27 Billion INR
Market Cap Rank
#23134 Global
#1286 in India
Share Price
Rs22.36
Change (1 day)
+4.39%
52-Week Range
Rs9.00 - Rs50.14
All Time High
Rs293.99
About

TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient c… Read more